Calls for papers
-
Virpax Pharmaceuticals announced that a study of its MMS019 powder “masking spray” in mice demonstrated “a marked inhibition of viral replication in the mouse nasal passages” for mice infected with SARS-CoV-2 and then given MMS019 intranasally… Read more . . .
-
Hovione Technology’s 8Shot dry powder inhaler has been selected as a finalist for the 2021 Medical Design Excellence Awards (MDEA) in the Drug-Delivery and Combination Products category, the company said. The 8Shot DPI, which is… Read more . . .
-
Nasus Pharma said that a bioequivalence study of its FMXIN001 dry powder intranasal naloxone demonstrated that FMXIN001 was absorbed significantly faster than Emergent BioSolutions’ Narcan naloxone nasal spray, with an AUC 163% of the Narcan… Read more . . .
-
GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing… Read more . . .
-
Johnson & Johnson has decided not to exercise an option acquired in a 2020 agreement with Pulmatrix for development and commercialization of Pulmatrix’s portfolio of inhaled narrow spectrum kinase inhibitors (NSKIs), including PUR1800. J&J’s Lung… Read more . . .
-
AIM ImmunoTech has announced that it will definitely advance an intranasal formulation of its Ampligen rintatolimod into a Phase 2 trial after the initial dose tested in a Phase 1 study showed no safety problems.… Read more . . .
-
According to Teva Pharmaceuticals Europe, the company has received marketing authorization in the EU for duplicate DPIs Seffalair Spiromax salmeterol xinafoate/ fluticasone propionate and BroPair Spiromax salmeterol xinafoate/ fluticasone propionate for the treatment for asthma… Read more . . .
-
Intravacc has announced that a pre-clinical study of its intranasal outer membrane vesicle (OMV)-based recombinant spike protein (rSP) vaccine candidate against SARS-CoV-2 nose spray vaccine in hamsters and mice demonstrated complete protection. The company announced… Read more . . .
-
Kindeva Drug Delivery has partnered with Cambridge Healthcare Innovations (CHI) for development and commercialization of CHI’s Aeolus DPI platform, the company said. The Aeolus device is breath-activated, blister-based, and comes in single use, reusable, and… Read more . . .
-
Seelos Therapeutics has signed a strategic device partnership agreement with Aptar Pharma for the use of Aptar’s Bidose Liquid System (BDS) for Seelos’ SLS-002 intranasal ketamine, Seelos said. SLS-002 is in Phase 2 development for the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK